- Home
- AXNX
AXNX
Axonics Inc.
as 11-12-2024 4:00pm EST
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 3.6B | IPO Year: | N/A |
| Target Price: | $71.00 | AVG Volume (30 days): | 383.5K |
| Analyst Decision: | Hold | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $54.00 - $70.75 | Next Earning Date: | 11-07-2024 |
| Revenue: | $431,902,000 | Revenue Growth: | 26.08% |
| Revenue Growth (this year): | 25.35% | Revenue Growth (next year): | 19.92% |
Stock Insider Trading Activity of Axonics Inc. (AXNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Keese Kari Leigh | AXNX | Chief Financial Officer | Oct 2 '24 | Sell | $69.41 | 2,961 | $205,512.25 | 42,959 |
Latest Axonics Inc. News
AXNX Breaking Stock News: Dive into AXNX Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates
Associated Press Finance
5 days ago
Axonics: Q3 Earnings Snapshot
Business Wire
5 days ago
Axonics Reports Third Quarter 2024 Financial Results
Zacks
15 days ago
Is Applied Therapeutics (APLT) Outperforming Other Medical Stocks This Year?
Insider Monkey
a month ago
Axonics, Inc. (AXNX): Strong Growth and Global Momentum in 2024
Business Wire
2 months ago
Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia
Business Wire
2 months ago
Axonics Prevails in Patent Infringement Lawsuit with Medtronic
Zacks
3 months ago
Axonics Modulation Technologies (AXNX) Surpasses Q2 Earnings and Revenue Estimates
Compare AXNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AXNX Axonics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.